Leveragen Secures Australian Patent for Singularity Platform Advancing Fully Human Single-Domain Antibody Discovery
Leveragen, Inc., a Boston-based biotechnology company advancing in vivo antibody discovery, today announced the grant of Australian Patent No. 2022271276 on September 3, 2026. Titled "Engineered Non-Human Animals for Producing Antibodies," the patent covers core innovations underlying the Singularity Platform. The grant follows the company's February 25, 2026, announcement of Japan Patent No. JP7799706, extending protection for its proprietary approach to single-domain antibody (sdAb) discovery.
Leveragen Announces Collaboration Agreement with Moderna Using Proprietary Fully Human Single Domain Antibody Technology to Advance Therapeutics
Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered a multi-target research, option and license agreement with Moderna, Inc.
Leveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody Platform
Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused on the development of therapeutic antibodies. This strategic collaboration utilizes Leveragen's proprietary Singularity Sapiens Mouse platform, a state-of-the-art technology for identifying and developing fully human single-domain antibodies, to facilitate the creation of multi-specific antibodies and other advanced therapeutics.
